Hematopoietic growth factors in rheumatoid arthritis: a critical approach to their use in view of possible adverse effects.
Vreugdenhil
G
G
Schattenberg
A
A
Dompeling
E C
EC
Swaak
A J
AJ
De Witte
T
T
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000503:physiopathology* / Q000517:prevention & control; D016026:Bone Marrow Transplantation; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000601:surgery; D008727:Methotrexate / Q000009:adverse effects*; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use
D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D016572:Cyclosporine; D011239:Prednisolone; D002955:Leucovorin; D008727:Methotrexate